Loading patent…
AssigneesThe Penn State Research Foundation, Virginia Commonwealth University
InventorsJanette M McAllister, Jerome F Strauss
Estimating the term…
Provided are compositions and methods for use in polycystic ovary syndrome diagnosis (PCOS). The method involves a sample from a subject for a DENND1A Variant 2 mRNA or DENND1 A Variant 2 protein to make or aid in a diagnosis of PCOS. Also provided are methods for selecting an individual as a candidate for therapy for polycystic ovary syndrome by testing a biological sample from an individual for DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein and designating the individual as a candidate for the PCOS based on determining DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein in the sample. Also provided are products for use in aiding diagnosis of PCOS which contain reagents for detecting DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein, and packaging containing printed material describing use and indications for the product.
A method for polycystic ovary syndrome diagnosis which comprises detection of DENND1A Variant 2 mRNA in a biological sample from a subject,
(canceled)
4-5. (canceled)
(canceled)
A method for polycystic ovary syndrome diagnosis which comprises detection of DENND1A Variant 2 protein in a biological sample from a subject, wherein detecting the DENND1A Variant 2 protein is performed using a composition comprising antibodies, wherein the antibodies are hybridized to the DENND1A Variant 2 protein, and wherein the hybridization of the antibodies to the DENND1A Variant 2 protein is detected.
A method for selecting an individual as a candidate for therapy for polycystic ovary syndrome, the method comprising testing a sample from the individual for DENND1A Variant 2 mRNA,
A product for use in aiding diagnosis of polycystic ovary syndrome, the product comprising packaging and at least two synthetic oligonucleotide probes and/or primers, wherein at least one of the probes and/or the primers can specifically hybridize to DENND1A Variant 2 mRNA, wherein the product further includes printed material indicating that the product is to be used to detect DENND1A Variant 2 mRNA as an indicator of polycystic ovary syndrome, the product optionally containing one or more sealed containers comprising reagents for use in hybridizing the one or more probes or the primers to the DENND1A Variant 2 mRNA.
A method for selecting an individual as a candidate for therapy for polycystic ovary syndrome, the method comprising testing a sample from the individual for DENND1A Variant 2 protein,
Dependencies are inferred from the claim text.